BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ATX-101: Phase III started

Kythera and Bayer's Intendis GmbH business began a pair of double-blind, placebo-controlled, European Phase III trials to evaluate ATX-101 in about 720 patients total. Last year,...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >